Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

1.

Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.

Mohebati A, Milne GL, Zhou XK, Duffield-Lillico AJ, Boyle JO, Knutson A, Bosworth BP, Kingsley PJ, Marnett LJ, Brown PH, Akpa EG, Szabo E, Dannenberg AJ.

Cancer Prev Res (Phila). 2013 Jul;6(7):646-55. doi: 10.1158/1940-6207.CAPR-13-0083. Epub 2013 May 16.

PMID:
23682075
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway.

Duffield-Lillico AJ, Boyle JO, Zhou XK, Ghosh A, Butala GS, Subbaramaiah K, Newman RA, Morrow JD, Milne GL, Dannenberg AJ.

Cancer Prev Res (Phila). 2009 Apr;2(4):322-9. doi: 10.1158/1940-6207.CAPR-09-0005. Epub 2009 Mar 31.

PMID:
19336727
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.

Li N, Sood S, Wang S, Fang M, Wang P, Sun Z, Yang CS, Chen X.

Clin Cancer Res. 2005 Mar 1;11(5):2089-96.

PMID:
15756036
[PubMed - indexed for MEDLINE]
Free Article
4.

Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.

Chen X, Wang S, Wu N, Sood S, Wang P, Jin Z, Beer DG, Giordano TJ, Lin Y, Shih WC, Lubet RA, Yang CS.

Clin Cancer Res. 2004 Oct 1;10(19):6703-9.

PMID:
15475461
[PubMed - indexed for MEDLINE]
Free Article
5.

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ.

J Clin Oncol. 2008 Feb 20;26(6):848-55. doi: 10.1200/JCO.2007.13.8081.

PMID:
18281656
[PubMed - indexed for MEDLINE]
Free Article
6.

The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKC delta.

Kwak HJ, Park KM, Choi HE, Lim HJ, Park JH, Park HY.

Cell Signal. 2010 Jan;22(1):80-7. doi: 10.1016/j.cellsig.2009.09.014. Epub 2009 Sep 22.

PMID:
19781629
[PubMed - indexed for MEDLINE]
7.

The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude.

Grissom CK, Richer LD, Elstad MR.

Chest. 2005 Feb;127(2):565-70.

PMID:
15705997
[PubMed - indexed for MEDLINE]
8.

Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.

Csiki I, Morrow JD, Sandler A, Shyr Y, Oates J, Williams MK, Dang T, Carbone DP, Johnson DH.

Clin Cancer Res. 2005 Sep 15;11(18):6634-40.

PMID:
16166442
[PubMed - indexed for MEDLINE]
Free Article
9.

The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.

Israel E, Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Shapiro J, Cohn J, Rubin P, Drazen JM.

Am Rev Respir Dis. 1993 Dec;148(6 Pt 1):1447-51.

PMID:
8256883
[PubMed - indexed for MEDLINE]
10.

Effects of zileuton and montelukast in mouse experimental spinal cord injury.

Genovese T, Rossi A, Mazzon E, Di Paola R, Muià C, Caminiti R, Bramanti P, Sautebin L, Cuzzocrea S.

Br J Pharmacol. 2008 Feb;153(3):568-82. Epub 2007 Dec 3.

PMID:
18059327
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.

Dovizio M, Tacconelli S, Ricciotti E, Bruno A, Maier TJ, Anzellotti P, Di Francesco L, Sala P, Signoroni S, Bertario L, Dixon DA, Lawson JA, Steinhilber D, FitzGerald GA, Patrignani P.

J Pharmacol Exp Ther. 2012 Apr;341(1):242-50. doi: 10.1124/jpet.111.190785. Epub 2012 Jan 19.

PMID:
22262921
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients.

Kekatpure VD, Boyle JO, Zhou XK, Duffield-Lillico AJ, Gross ND, Lee NY, Subbaramaiah K, Morrow JD, Milne G, Lippman SM, Dannenberg AJ.

Cancer Prev Res (Phila). 2009 Nov;2(11):957-65. doi: 10.1158/1940-6207.CAPR-09-0093. Epub 2009 Oct 20.

PMID:
19843689
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Celecoxib inhibits 5-lipoxygenase.

Maier TJ, Tausch L, Hoernig M, Coste O, Schmidt R, Angioni C, Metzner J, Groesch S, Pergola C, Steinhilber D, Werz O, Geisslinger G.

Biochem Pharmacol. 2008 Oct 1;76(7):862-72. doi: 10.1016/j.bcp.2008.07.009. Epub 2008 Jul 19.

PMID:
18692027
[PubMed - indexed for MEDLINE]
14.

Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor.

Kane GC, Tollino M, Pollice M, Kim CJ, Cohn J, Murray JJ, Dworski R, Sheller J, Fish JE, Peters SP.

Prostaglandins. 1995 Jul;50(1):1-18.

PMID:
8588068
[PubMed - indexed for MEDLINE]
15.

The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages.

Rossi A, Pergola C, Koeberle A, Hoffmann M, Dehm F, Bramanti P, Cuzzocrea S, Werz O, Sautebin L.

Br J Pharmacol. 2010 Oct;161(3):555-70. doi: 10.1111/j.1476-5381.2010.00930.x.

PMID:
20880396
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus.

Hackshaw KV, Shi Y, Brandwein SR, Jones K, Westcott JY.

J Rheumatol. 1995 Mar;22(3):462-8.

PMID:
7783062
[PubMed - indexed for MEDLINE]
17.

The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.

Israel E, Rubin P, Kemp JP, Grossman J, Pierson W, Siegel SC, Tinkelman D, Murray JJ, Busse W, Segal AT, Fish J, Kaiser HB, Ledford D, Wenzel S, Rosenthal R, Cohn J, Lanni C, Pearlman H, Karahalios P, Drazen JM.

Ann Intern Med. 1993 Dec 1;119(11):1059-66.

PMID:
8239223
[PubMed - indexed for MEDLINE]
18.

Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization.

Woodruff PG, Albert RK, Bailey WC, Casaburi R, Connett JE, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Harnden SM, Kim V, Marchetti N, Martinez FJ, McEvoy CE, Niewoehner DE, Reilly JJ, Rice K, Scanlon PD, Scharf SM, Sciurba FC, Washko GR, Lazarus SC; Copd Clinical Research Network.

COPD. 2011 Feb;8(1):21-9. doi: 10.3109/15412555.2010.540273.

PMID:
21299475
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.

Horrillo R, Planagumà A, González-Périz A, Ferré N, Titos E, Miquel R, López-Parra M, Masferrer JL, Arroyo V, Clària J.

J Pharmacol Exp Ther. 2007 Dec;323(3):778-86. Epub 2007 Aug 31.

PMID:
17766677
[PubMed - indexed for MEDLINE]
Free Article
20.

Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.

Tagari P, Brideau C, Chan C, Frenette R, Black C, Ford-Hutchinson A.

Agents Actions. 1993 Sep;40(1-2):62-71.

PMID:
8147271
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk